Viewing Study NCT03379051


Ignite Creation Date: 2025-12-24 @ 11:42 PM
Ignite Modification Date: 2026-02-22 @ 9:44 PM
Study NCT ID: NCT03379051
Status: TERMINATED
Last Update Posted: 2022-08-22
First Post: 2017-12-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
Sponsor: TG Therapeutics, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module